Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company's second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:PIRS
- CUSIP: N/A
- Web: www.pieris.com
Capitalization:- Market Cap: $233.95 million
- Outstanding Shares: 44,309,000
Average Prices:- 50 Day Moving Avg: $5.39
- 200 Day Moving Avg: $5.39
- 52 Week Range: $1.30 - $5.49
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.21
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $6.71 million
- Price / Sales: 34.87
- Book Value: $0.21 per share
- Price / Book: 25.14
Profitability:- EBIDTA: ($27,990,000.00)
- Net Margins: -459.73%
- Return on Equity: -146.72%
- Return on Assets: -50.02%
Debt:- Current Ratio: 2.87%
- Quick Ratio: 2.87%
Misc:- Average Volume: 245,014 shs.
- Beta: 1.79
- Short Ratio: 3.7
Frequently Asked Questions for Pieris Pharmaceuticals (NASDAQ:PIRS)
What is Pieris Pharmaceuticals' stock symbol?
Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."
How were Pieris Pharmaceuticals' earnings last quarter?
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) released its quarterly earnings data on Wednesday, May, 10th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.16 by $0.35. The business earned $1.34 million during the quarter, compared to the consensus estimate of $32.30 million. Pieris Pharmaceuticals had a negative net margin of 459.73% and a negative return on equity of 146.72%. View Pieris Pharmaceuticals' Earnings History.
Where is Pieris Pharmaceuticals' stock going? Where will Pieris Pharmaceuticals' stock price be in 2017?
4 equities research analysts have issued 1-year price targets for Pieris Pharmaceuticals' stock. Their forecasts range from $6.00 to $9.00. On average, they anticipate Pieris Pharmaceuticals' share price to reach $8.25 in the next year. View Analyst Ratings for Pieris Pharmaceuticals.
Who are some of Pieris Pharmaceuticals' key competitors?
Some companies that are related to Pieris Pharmaceuticals include GlycoMimetics (GLYC), NantKwest (NK), Madrigal Pharmaceuticals (MDGL), AVEO Pharmaceuticals (AVEO), Selecta Biosciences (SELB), Mersana Therapeutics (MRSN), Urogen Pharma (URGN), Bellicum Pharmaceuticals (BLCM), Merus N.V. (MRUS), Corbus Pharmaceuticals Holdings (CRBP), Geron Corporation (GERN), Kura Oncology (KURA), BioSpecifics Technologies Corp (BSTC), RA PHARMCTL INC (RARX), CymaBay Therapeutics (CBAY), BioTime (BTX), Akebia Therapeutics (AKBA) and Edge Therapeutics (EDGE).
Who are Pieris Pharmaceuticals' key executives?
Pieris Pharmaceuticals' management team includes the folowing people:
- Chau Quang Khuong, Independent Chairman of the Board
- Stephen S. Yoder, President, Chief Executive Officer, Director
- Lance E. Thibault, Acting Chief Financial Officer
- Claude Knopf, Senior Vice President, Chief Business Officer
- Louis A. Matis M.D., Senior Vice President and Chief Development Officer
- Julian Adams, Director
- Jean-Pierre Bizzari M.D., Director
- James A. Geraghty, Director
- Christopher P. Kiritsy, Director
- Steven Prelack, Independent Director
Who owns Pieris Pharmaceuticals stock?
Pieris Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Tekla Capital Management LLC (6.54%), Omega Fund Management LLC (3.17%), Sphera Funds Management LTD. (2.55%), State Street Corp (1.08%), Northern Trust Corp (0.75%) and TIAA CREF Investment Management LLC (0.30%). Company insiders that own Pieris Pharmaceuticals stock include Allan Reine, Darlene M Deptula-Hicks, James A Geraghty, Louis Matis and Stephen S Yoder. View Institutional Ownership Trends for Pieris Pharmaceuticals.
Who sold Pieris Pharmaceuticals stock? Who is selling Pieris Pharmaceuticals stock?
Who bought Pieris Pharmaceuticals stock? Who is buying Pieris Pharmaceuticals stock?
Pieris Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Northern Trust Corp, TIAA CREF Investment Management LLC, Vanguard Group Inc., Sphera Funds Management LTD., Bank of New York Mellon Corp, Teachers Advisors LLC and California State Teachers Retirement System. Company insiders that have bought Pieris Pharmaceuticals stock in the last two years include Allan Reine, Darlene M Deptula-Hicks, James A Geraghty, Louis Matis and Stephen S Yoder. View Insider Buying and Selling for Pieris Pharmaceuticals.
How do I buy Pieris Pharmaceuticals stock?
Shares of Pieris Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pieris Pharmaceuticals' stock price today?
One share of Pieris Pharmaceuticals stock can currently be purchased for approximately $5.28.
MarketBeat Community Rating for Pieris Pharmaceuticals (NASDAQ PIRS)MarketBeat's community ratings are surveys of what our community members think about Pieris Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Pieris Pharmaceuticals (NASDAQ:PIRS) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 4 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $8.25 (56.25% upside) |
Analysts' Ratings History for Pieris Pharmaceuticals (NASDAQ:PIRS)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/11/2017 | HC Wainwright | Set Price Target | Buy | $9.00 | High |  |
| 5/30/2017 | Rodman & Renshaw | Initiated Coverage | Buy -> Buy | $9.00 | High | |
| 4/12/2017 | Oppenheimer Holdings, Inc. | Set Price Target | Buy | $9.00 | Low | |
| 9/28/2016 | Roth Capital | Reiterated Rating | Buy | $6.00 | N/A | |
| 3/9/2016 | JMP Securities | Lower Price Target | Market Outperform | $10.00 -> $9.00 | N/A | |
(Data available from 9/25/2015 forward)
Earnings History for Pieris Pharmaceuticals (NASDAQ:PIRS)Earnings History by Quarter for Pieris Pharmaceuticals (NASDAQ PIRS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/10/2017 | Q1 2017 | $0.16 | ($0.19) | $32.30 million | $1.34 million | View | N/A | |
| 8/10/2016 | Q216 | ($0.15) | ($0.14) | $1.08 million | $1.07 million | View | N/A | |
| 5/11/2016 | Q116 | ($0.12) | ($0.10) | $6.40 million | $1.25 million | View | N/A | |
| 3/23/2016 | Q415 | ($0.12) | ($0.07) | $3.27 million | $2.14 million | View | N/A | |
| 11/11/2015 | Q315 | ($0.11) | ($0.10) | $0.23 million | $0.42 million | View | N/A | |
| 8/12/2015 | Q215 | ($0.14) | ($0.12) | $0.25 million | $0.16 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Pieris Pharmaceuticals (NASDAQ:PIRS)2017 EPS Consensus Estimate: $0.05
2018 EPS Consensus Estimate: ($0.86)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | $0.52 | $0.52 | $0.52 |
| Q2 2017 | 1 | ($0.22) | ($0.22) | ($0.22) |
| Q3 2017 | 1 | ($0.23) | ($0.23) | ($0.23) |
| Q4 2017 | 1 | ($0.02) | ($0.02) | ($0.02) |
| Q1 2018 | 1 | ($0.23) | ($0.23) | ($0.23) |
| Q2 2018 | 1 | ($0.22) | ($0.22) | ($0.22) |
| Q3 2018 | 1 | ($0.20) | ($0.20) | ($0.20) |
| Q4 2018 | 1 | ($0.21) | ($0.21) | ($0.21) |
(Data provided by Zacks Investment Research)
Dividend History for Pieris Pharmaceuticals (NASDAQ:PIRS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Pieris Pharmaceuticals (NASDAQ:PIRS)Insider Ownership Percentage: 4.05%
Institutional Ownership Percentage: 50.50%
Insider Trades by Quarter for Pieris Pharmaceuticals (NASDAQ:PIRS)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/17/2017 | Allan Reine | Insider | Buy | 65,000 | $4.82 | $313,300.00 | |
| 8/17/2017 | James A Geraghty | Director | Buy | 10,000 | $4.82 | $48,200.00 | |
| 6/14/2016 | Louis Matis | SVP | Buy | 10,000 | $1.70 | $17,000.00 | |
| 6/13/2016 | Darlene M Deptula-Hicks | CFO | Buy | 5,000 | $1.66 | $8,300.00 | |
| 6/13/2016 | Stephen S Yoder | CEO | Buy | 6,000 | $1.68 | $10,080.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Pieris Pharmaceuticals (NASDAQ:PIRS)
Latest Headlines for Pieris Pharmaceuticals (NASDAQ:PIRS)
| Source: |
|
| Date | Headline |
|---|
 | Is Pieris Pharmaceuticals Inc (PIRS) Undervalued?
finance.yahoo.com - September 16 at 7:48 AM |
 | Pieris Pharmaceuticals (PIRS) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 14 at 9:15 AM |
 | Pieris Pharmaceuticals, Inc. (PIRS) Expected to Post Earnings of -$0.21 Per Share
www.americanbankingnews.com - September 9 at 8:42 AM |
| Pieris Pharmaceuticals, Inc. (PIRS) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - September 5 at 6:28 AM |
| Pieris Pharmaceuticals: Favorable Collaboration Terms Point To Continued Upside
seekingalpha.com - August 25 at 10:06 AM |
| $1.73 Million in Sales Expected for Pieris Pharmaceuticals, Inc. (PIRS) This Quarter
www.americanbankingnews.com - August 23 at 7:28 AM |
| Zacks: Brokerages Anticipate Pieris Pharmaceuticals, Inc. (PIRS) Will Announce Earnings of -$0.21 Per Share
www.americanbankingnews.com - August 21 at 4:22 PM |
| Oppenheimer Holdings Comments on Pieris Pharmaceuticals, Inc.'s FY2017 Earnings (PIRS)
www.americanbankingnews.com - August 21 at 5:10 AM |
| Insider Buying: Pieris Pharmaceuticals, Inc. (PIRS) Director Acquires 10,000 Shares of Stock
www.americanbankingnews.com - August 17 at 10:48 PM |
| Pieris Pharmaceuticals, Inc. (PIRS) Insider Allan Reine Buys 65,000 Shares
www.americanbankingnews.com - August 17 at 10:26 PM |
| Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Given a $9.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - August 13 at 3:32 PM |
| Pieris Pharmaceuticals, Inc. (PIRS) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - August 11 at 5:06 PM |
 | Pieris Pharma (PIRS) Appoints Allan Reine as CFO
www.streetinsider.com - August 11 at 7:33 AM |
| Pieris Pharmaceuticals Appoints Allan Reine, M.D., as Chief Financial Officer
finance.yahoo.com - August 11 at 7:33 AM |
| Edited Transcript of PIRS earnings conference call or presentation 10-Aug-17 2:00pm GMT
finance.yahoo.com - August 11 at 7:33 AM |
| Pieris Pharmaceuticals Reports Financial Results for the Second Quarter Ended June 30, 2017 and Provides Corporate Update
finance.yahoo.com - August 10 at 6:52 AM |
| Pieris Pharmaceuticals reports 2Q loss
finance.yahoo.com - August 10 at 6:52 AM |
| Zacks: Analysts Anticipate Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Will Announce Quarterly Sales of $3.75 Million
www.americanbankingnews.com - August 5 at 7:14 AM |
| Pieris Pharmaceuticals, Inc. (PIRS) Expected to Post Earnings of -$0.14 Per Share
www.americanbankingnews.com - August 3 at 10:14 AM |
| Pieris Pharmaceuticals to Host Second Quarter 2017 Investor Call and Corporate Update on August 10, 2017
finance.yahoo.com - August 1 at 4:26 PM |
| Pieris Pharmaceuticals, Inc. (PIRS) Sees Large Increase in Short Interest
www.americanbankingnews.com - July 16 at 7:14 AM |
| Zacks: Analysts Anticipate Pieris Pharmaceuticals, Inc. (PIRS) Will Post Quarterly Sales of $3.75 Million
www.americanbankingnews.com - July 14 at 4:22 PM |
| OpCo On Biotech: 'Our Bullishness Is Unabated'
finance.yahoo.com - July 13 at 7:59 AM |
| Zacks: Analysts Expect Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Will Post Earnings of -$0.14 Per Share
www.americanbankingnews.com - July 12 at 7:54 AM |
| Pieris Pharmaceuticals Announces Results from 2017 Annual Meeting of Stockholders and Provides Update on Therapeutic Programs
finance.yahoo.com - July 6 at 7:59 AM |
| ETFs with exposure to Pieris Pharmaceuticals, Inc. : July 4, 2017
finance.yahoo.com - July 5 at 9:36 AM |
| These 3 Small Biotechs Have a Healthy Shot
finance.yahoo.com - June 28 at 4:34 PM |
| Pieris Pharmaceuticals Added to the Russell 2000(R) and Russell 3000(R) Indexes
finance.yahoo.com - June 27 at 7:20 PM |
 | Health Care Stocks Are Crushing the S&P 500 (JNJ, SNY, AZN) - Investopedia
www.investopedia.com - June 19 at 10:25 AM |
| $3.75 Million in Sales Expected for Pieris Pharmaceuticals, Inc. (PIRS) This Quarter
www.americanbankingnews.com - June 18 at 10:26 AM |
| Pieris Pharmaceuticals, Inc. (PIRS) Stock Rating Lowered by TheStreet
www.americanbankingnews.com - June 15 at 9:26 PM |
| Short Interest in Pieris Pharmaceuticals, Inc. (PIRS) Declines By 32.6%
www.americanbankingnews.com - June 13 at 7:18 AM |
| Pieris Pharma (PIRS) Reports Expiration of HSR Waiting Period for Collaboration with AstraZeneca (AZN)
www.streetinsider.com - June 12 at 6:52 PM |
| Pieris Pharmaceuticals (PIRS) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 12 at 6:52 PM |
| Pieris Pharmaceuticals Announces Expiration of HSR Waiting Period for Collaboration with AstraZeneca
finance.yahoo.com - June 12 at 8:33 AM |
| Pieris Pharmaceuticals Announces Presentation of Clinical Data for Anemia Drug Candidate, PRS-080, at the 54th ERA-EDTA Congress
finance.yahoo.com - June 4 at 9:34 AM |
| Pieris Pharmaceuticals, Inc. :PIRS-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 9:46 PM |
| Pieris Pharmaceuticals to Present at The Jefferies 2017 Global Healthcare Conference on Friday, June 9th at 9:00 am EDT
finance.yahoo.com - June 1 at 8:05 PM |
| Pieris Pharmaceuticals Inc (PIRS) Now Covered by Analysts at Rodman & Renshaw
www.americanbankingnews.com - May 30 at 6:58 PM |
| Pieris Pharmaceuticals Inc (PIRS) Short Interest Update
www.americanbankingnews.com - May 28 at 7:00 AM |
| Pieris Pharmaceuticals Appoints James Geraghty to its Board of Directors
finance.yahoo.com - May 22 at 6:24 PM |
| Pieris Pharmaceuticals Inc (PIRS) Expected to Earn Q1 2018 Earnings of ($0.22) Per Share
www.americanbankingnews.com - May 15 at 9:06 AM |
| Pieris Pharmaceuticals Inc (PIRS) Issues Earnings Results
www.americanbankingnews.com - May 11 at 7:18 PM |
| Pieris Pharmaceuticals Reports Financial Results for the First Quarter Ended March 31, 2017 and Provides Corporate Update
finance.yahoo.com - May 10 at 7:28 PM |
| Pieris Pharmaceuticals reports 1Q loss
finance.yahoo.com - May 10 at 7:28 PM |
| Pieris Pharmaceuticals (PIRS) Earns Daily Coverage Optimism Score of 0.31
www.americanbankingnews.com - May 8 at 11:45 PM |
| Pieris Pharmaceuticals Inc (PIRS) Rating Increased to C- at TheStreet
www.americanbankingnews.com - May 6 at 11:52 PM |
 | Gainers & Losers Of May 3: PIRS, MYGN, XENT, RXDX, SPPI...
www.finanznachrichten.de - May 5 at 12:26 AM |
| Pieris Pharmaceuticals (PIRS) Earning Somewhat Favorable News Coverage, Study Shows
www.americanbankingnews.com - May 4 at 11:17 AM |
| Zacks: Pieris Pharmaceuticals Inc (PIRS) Given Consensus Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - May 4 at 8:12 AM |
Pieris Pharmaceuticals (PIRS) Chart for Monday, September, 25, 2017
